{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:28:08Z","timestamp":1782937688485,"version":"3.54.5"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81202454"],"award-info":[{"award-number":["81202454"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangdong Province","award":["2013B090500046"],"award-info":[{"award-number":["2013B090500046"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.steroids.2017.02.003","type":"journal-article","created":{"date-parts":[[2017,3,5]],"date-time":"2017-03-05T07:01:47Z","timestamp":1488697307000},"page":"10-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Development of 17\u03b2-hydroxysteroid dehydrogenase type 3 as a target in hormone-dependent prostate cancer therapy"],"prefix":"10.1016","volume":"121","author":[{"given":"Xiaohui","family":"Ning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.steroids.2017.02.003_b0005","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev.pharmtox.47.120505.105337","article-title":"Aldo-keto reductases and bioactivation\/detoxication","volume":"47","author":"Jin","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"3","key":"10.1016\/j.steroids.2017.02.003_b0010","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1124\/jpet.105.091587","article-title":"Tibolone metabolism in human liver is catalyzed by 3\u03b1\/3\u03b2-hydroxysteroid dehydrogenase activities of the four isoforms of the aldo-keto reductase (AKR)1C subfamily","volume":"316","author":"Steckelbroeck","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1\u20132","key":"10.1016\/j.steroids.2017.02.003_b0015","first-page":"183","article-title":"Reductive 17\u03b2-hydroxysteroid dehydrogenases in the sulfatase pathway: critical in the cell proliferation of breast cancer","volume":"301","author":"Akz","year":"2006","journal-title":"J. Mol Cell Endocrinol."},{"key":"10.1016\/j.steroids.2017.02.003_b0020","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.urology.2012.12.024","article-title":"Novel mutation among two sisters with 17\u03b2-hydroxysteroid dehydrogenase type 3 deficiency","volume":"81","author":"Massanyi","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.steroids.2017.02.003_b0025","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1111\/j.1743-6109.2012.02763.x","article-title":"A novel nonsense mutation in HSD17B3 gene in a tunisian patient with sexual ambiguity","volume":"10","author":"Rhouma","year":"2013","journal-title":"J. Sex Med."},{"key":"10.1016\/j.steroids.2017.02.003_b0030","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.steroids.2015.03.008","article-title":"Synthesis of methoxycarbonyl pyrazolyl androstene derivatives, and their potential inhibitory effect on androgen biosynthesis and cell proliferation","volume":"98","author":"Szab\u00f3","year":"2015","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2017.02.003_b0035","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jsbmb.2013.12.019","article-title":"In vitro and in vivo evaluation of a 3\u03b2-androsterone derivative as inhibitor of 17\u03b2-hydroxysteroid dehydrogenase type 3","volume":"141","author":"Roy","year":"2014","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2017.02.003_b0040","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000318004","article-title":"The clinical and molecular heterogeneity of 17\u03b2-HSD3 enzyme deficiency","volume":"74","author":"George","year":"2010","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.steroids.2017.02.003_b0045","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.steroids.2007.10.009","article-title":"Proliferative effect of androst-4-ene-3,17-dione and its metabolites in the androgen-sensitive LNCaP cell line","volume":"73","author":"Laplante","year":"2008","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2017.02.003_b0050","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/pros.10139","article-title":"Differential expression of 17\u03b2-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues","volume":"53","author":"Koh","year":"2002","journal-title":"Prostate"},{"key":"10.1016\/j.steroids.2017.02.003_b0055","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10637-007-9070-7","article-title":"Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines","volume":"25","author":"Biancolella","year":"2007","journal-title":"Invest. New Drugs"},{"issue":"24","key":"10.1016\/j.steroids.2017.02.003_b0060","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1007\/s00018-008-8588-y","article-title":"The SDR superfamily: functional and structural diversity within a family of metabolic and regulatory enzymes","volume":"65","author":"Kavanagh","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"issue":"11","key":"10.1016\/j.steroids.2017.02.003_b0065","first-page":"2010","article-title":"S.X. LinCritical residues for the specificity of cofactors and substrates in human estro-genic 17beta-hydroxysteroid dehydrogenase 1: variants designed from the three-dimensional structure of the enzyme","volume":"15","author":"Huang","year":"2001","journal-title":"Mol. Endocrinol."},{"issue":"1","key":"10.1016\/j.steroids.2017.02.003_b0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1570-9639(02)00434-X","article-title":"Amino acid substitution of arginine 80 in 17beta-hydroxysteroid dehydrogenase type 3 and its effect on NADPH cofactor binding and oxidation\/reduction kinetics","volume":"1601","author":"McKeever","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.steroids.2017.02.003_b0075","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.mce.2005.12.007","article-title":"Structure and function of human 17\u03b2-hydroxysteroid dehydrogenases","volume":"248","author":"Lukacik","year":"2006","journal-title":"Mol. Cell. Endocrinol."},{"issue":"1\u20132","key":"10.1016\/j.steroids.2017.02.003_b0080","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0960-0760(96)00165-3","article-title":"Sequence of mouse 17beta-hydroxysteroid dehydrogenase type 3 cDNA and tissue distribution of the type 1 and type 3 isoform mRNAs","volume":"60","author":"Sha","year":"1997","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.steroids.2017.02.003_b0085","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: mechanism for castration-resistant tumor growth","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.steroids.2017.02.003_b0090","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-07-5997","article-title":"Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer","volume":"68","author":"Locke","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.steroids.2017.02.003_b0095","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/pros.10134","article-title":"Association of the G289S single nucleotide polymorphism in the HSD17B3 gene with prostate cancer in Italian men","volume":"53","author":"Margiotti","year":"2002","journal-title":"Prostate"},{"key":"10.1016\/j.steroids.2017.02.003_b0100","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1160\/TH05-01-0037","article-title":"Platelets express steroidogenic 17\u03b2-hydroxysteroid dehydrogenases: distinct profiles predict the essential thrombocythemic phenotype","volume":"94","author":"Gnatenko","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.steroids.2017.02.003_b0105","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.steroids.2017.02.003_b0110","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches, mechanisms of prostate cancer progression","volume":"32","author":"Arantanos","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.steroids.2017.02.003_b0115","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.steroids.2012.03.015","article-title":"Steroid biosynthesis and prostate cancer","volume":"77","author":"Sharifi","year":"2012","journal-title":"Steroids"},{"key":"10.1016\/j.steroids.2017.02.003_b0120","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1043-2760(00)00342-8","article-title":"Role of 17 beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues","volume":"11","author":"Labrie","year":"2000","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.steroids.2017.02.003_b0125","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0022-5347(05)67290-4","article-title":"Failure to achieve castrate levels of T during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum T and a treatment decision algorithm","volume":"164","author":"Oefelein","year":"2000","journal-title":"J. Urol."},{"key":"10.1016\/j.steroids.2017.02.003_b0130","doi-asserted-by":"crossref","first-page":"39953","DOI":"10.1074\/jbc.M110.158063","article-title":"GPRC6A mediates the non-genomic effects of steroids","volume":"285","author":"Pi","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.steroids.2017.02.003_b0135","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1158\/2159-8290.CD-13-0226","article-title":"A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509","volume":"3","author":"Joseph","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.steroids.2017.02.003_b0140","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1200\/jco.2016.34.2_suppl.73","article-title":"Differential side effects profile in mCRPC patients treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials","volume":"34","author":"Moreira","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.steroids.2017.02.003_b0145","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/jco.2014.32.4_suppl.240","article-title":"Enzalutamide after abiraterone in patients with metastatic castrate-resistant prostate cancer (mCRPC)","volume":"32","author":"Sandhu","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.steroids.2017.02.003_b0150","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.mce.2008.08.014","article-title":"Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17\u03b2-hydroxysteroid dehydrogenase Type 3","volume":"301","author":"Day","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.steroids.2017.02.003_b0155","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jsbmb.2011.01.016","article-title":"Identification of chemically diverse, novel inhibitors of 17\u03b2-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening","volume":"125","author":"Schuster","year":"2011","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"6","key":"10.1016\/j.steroids.2017.02.003_b0160","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2174\/0929867033368222","article-title":"Inhibitors of 17\u03b2-hydroxysteroid dehydrogenases","volume":"10","author":"Poirier","year":"2003","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.steroids.2017.02.003_b0165","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2174\/187221407780831957","article-title":"Hydroxysteroid dehydrogenase (17\u03b2-HSD3, 17\u03b2-HSD5, and 3\u03b2-HSD3) inhibitors: extragonadal regulation of intracellular sex steroid hormone levels","volume":"1","author":"Mohler","year":"2007","journal-title":"Recent Patents Endocr. Metab. Immune Drug Discov."},{"key":"10.1016\/j.steroids.2017.02.003_b0170","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1517\/13543776.2010.505604","article-title":"17\u03b2-Hydroxysteroid dehydrogenase inhibitors: a patent review","volume":"20","author":"Poirier","year":"2010","journal-title":"Exp. Opin. Ther. Patents"},{"key":"10.1016\/j.steroids.2017.02.003_b0175","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1677\/ERC-08-0042","article-title":"Design and validation of specific inhibitors of 17\u03b2-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis","volume":"15","author":"Day","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.steroids.2017.02.003_b0180","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/1872214809666150201214602","article-title":"Recent patents on new steroid agents targeting the steroidogenesis for endocrine cancer treatments","volume":"9","author":"Poirier","year":"2015","journal-title":"Recent Patents Endocr. Metab. Immune Drug Discov."},{"key":"10.1016\/j.steroids.2017.02.003_b0185","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1016\/j.bmc.2015.07.049","article-title":"Design, chemical synthesis and biological evaluation of 3-spiromorpholinone\/3-spirocarbamate androsterone derivatives as inhibitors of 17\u03b2-hydroxysteroid dehydrogenase type 3","volume":"23","author":"Djigou\u00e9","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.steroids.2017.02.003_b0190","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1016\/j.bmc.2011.06.003","article-title":"Development of 3-substituted-androsterone derivatives as potent inhibitors of 17\u03b2-hydroxysteroid dehydrogenase type 3","volume":"19","author":"Maltais","year":"2011","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.steroids.2017.02.003_b0195","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1248\/cpb.c13-00961","article-title":"Synthesis of a human urate transporter-1 inhibitor, an arginine vasopressin antagonist, and a 17\u03b2-hydroxysteroid dehydrogenase type-3 inhibitor, using ring-expansion of cyclic ketoximes with DIBALH","volume":"62","author":"Cho","year":"2014","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.steroids.2017.02.003_b0200","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.bcp.2009.12.005","article-title":"The UV-filter benzophenone-1 inhibits 17\u03b2-hydroxysteroid dehydrogenase type 3: virtual screening as a strategy to identify potential endocrine disrupting chemicals","volume":"79","author":"Nashev","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.steroids.2017.02.003_b0205","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1530\/ERC-12-0231","article-title":"STX2171, a 17\u03b2-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model","volume":"20","author":"Day","year":"2013","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.steroids.2017.02.003_b0210","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.bmcl.2011.10.095","article-title":"Identification of oxazolidinediones and thiazolidinediones as potent 17\u03b2-hydroxysteroid dehydrogenase type 3 inhibitors","volume":"22","author":"Harad","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.steroids.2017.02.003_b0215","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1016\/j.bmc.2012.03.052","article-title":"Discovery of potent and orally bioavailable 17\u03b2\u2013hydroxysteroid dehydrogenase type 3 inhibitors","volume":"20","author":"Harada","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.steroids.2017.02.003_b0220","first-page":"069","article-title":"Synthesis of a dansyl-labeled inhibitor of 17\u03b2-hydroxysteroid dehydrogenase type 3 for optical imaging","volume":"03","author":"Kenmogne","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.steroids.2017.02.003_b0225","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrd2290","article-title":"Molecular imaging in drug development","volume":"7","author":"Willmann","year":"2008","journal-title":"Nat. Rev. Drug Disc."}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X17300351?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X17300351?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T13:31:49Z","timestamp":1692711109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X17300351"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":45,"alternative-id":["S0039128X17300351"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2017.02.003","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of 17\u03b2-hydroxysteroid dehydrogenase type 3 as a target in hormone-dependent prostate cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2017.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}